AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-MycB-cell lymphomain vivo

Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53

(2012) Megan J. Bywater et al.   CANCER CELL

Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer

(2012) T. Sangai et al.   CLINICAL CANCER RESEARCH

Combination of an Allosteric Akt Inhibitor MK-2206 with Etoposide or Rapamycin Enhances the Antitumor Growth Effect in Neuroblastoma

(2012) Z. Li et al.   CLINICAL CANCER RESEARCH

The translational landscape of mTOR signalling steers cancer initiation and metastasis

(2012) Andrew C. Hsieh et al.   NATURE

mTOR Inhibitors Synergize on Regression, Reversal of Gene Expression, and Autophagy in Hepatocellular Carcinoma

(2012) H. E. Thomas et al.   Science Translational Medicine

The mTORC1 Inhibitor Everolimus Prevents and Treats Eμ- Myc Lymphoma by Restoring Oncogene-Induced Senescence

(2012) Meaghan Wall et al.   Cancer Discovery

Oncogenic AKTivation of translation as a therapeutic target

(2011) A C Hsieh et al.   BRITISH JOURNAL OF CANCER

Signaling to the ribosome in cancer-It is more than just mTORC1

(2011) Katherine M. Hannan et al.   IUBMB LIFE

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

AKT Promotes rRNA Synthesis and Cooperates with c-MYC to Stimulate Ribosome Biogenesis in Cancer

(2011) J. C. Chan et al.   Science Signaling

Genomic Complexity and AKT Dependence in Serous Ovarian Cancer

(2011) Aphrothiti J. Hanrahan et al.   Cancer Discovery

Targeting RNA Polymerase I with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth

(2010) Denis Drygin et al.   CANCER RESEARCH

Class IA Phosphatidylinositol 3-Kinase Signaling in Non-small Cell Lung Cancer

(2010) Benjamin Solomon et al.   Journal of Thoracic Oncology

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

(2010) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

c-MYC coordinately regulates ribosomal gene chromatin remodeling and Pol I availability during granulocyte differentiation

(2010) Gretchen Poortinga et al.   NUCLEIC ACIDS RESEARCH

The Role of Myc-Induced Protein Synthesis in Cancer

(2009) D. Ruggero   CANCER RESEARCH

Current Perspectives on Akt Akt-ivation and Akt-ions

(2009) Ronald W. Matheny et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis

(2008) Neil P. Shah et al.   CANCER CELL

Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency

(2008) Maria Barna et al.   NATURE

Apoptotic signaling by c-MYC

(2008) B Hoffman et al.   ONCOGENE